All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Machine-learning algorithms have been shown to make medical diagnoses as accurate as doctors in the field of cardiology, dermatology, and oncology.1,2,3 By using machine-learning approaches, diagnostic success may be increased whilst human error rate could be reduced. Jocelyn S. Gandelman from Vanderbilt University Medical Center, Nashville, TN, USA, and colleagues published a study ahead of print in Haematologica assessing machine-learning methods in chronic graft-versus-host disease (cGvHD) patients to identify distinct clusters of phenotypes and survival patterns.4
The study group investigated whether a machine-learning algorithm could diagnose patients according to organ scores, identify phenotypic subgroups and also stratify survival. Clinical data was used from 339 patients.
This study shows that machine-learning is promising in terms of identifying biomarkers and stratifying risk in patients with cGvHD. The authors stated that “these results have the potential to be applied to stratify risk in the clinical setting, enhance the current cGvHD classification system, refine inclusion criteria for phase II trials, and guide biomarker discovery for more specific therapeutic targets.” Further studies are required to confirm this data.
Subscribe to get the best content related to GvHD delivered to your inbox